NCT07444892CompletedPhase 2
Levodopa for Diabetic Retinopathy
Source: ClinicalTrials.gov · Last updated 3 Mar 2026
Brief summary (registry, in English)
The purpose of this study is to determine optimum dosing strategies of levodopa and determine the physiologic mechanisms that provide the therapeutic response to restore abnormalities in the electrical conductivity of the retina in people with diabetes and no clinically visible retinopathy.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 230 (actual)
- First submitted
- 25 Feb 2026
- Start date
- Apr 2022
- Primary completion date
- Nov 2025
- Lead sponsor
- Emory University
- Diseases
- Diabetic eye disease
- NCT number
- NCT07444892
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 230
- From Apr 2022 to the primary completion date, Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- taking dopamine effecting drugs
Other illness
- psychosis, Parkinson's disease
- confounding ocular disease
- Control Participants:
- Non-diabetic participants with no visual problems to create control measurements.
Other
- have a pituitary tumor
- cognitive deficits
Who the study is looking for
- Adults
- diagnosed with diabetes mellitus
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Atlanta VA Medical Center Coordinator of this site? Confirm its status | Decatur | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.